Uncertainty is fact of life for regulators. FDA officials make drug approval decisions based on inherently incomplete data. Even the largest clinical study can’t answer every question about how a medicine will perform in the real world—and, indeed, the larger the trial the more new questions are likely to arise if you dig deeply into the data.
As Center for Drug Evaluation & Research Director Janet Woodcock put it in her opening remarks to a Feb. 12...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?